Blinatumomab: Phase III started

The ECOG-ACRIN Cancer Research Group began the open-label, U.S. Phase III E1910 trial to compare Amgen's blinatumomab plus chemotherapy vs. chemotherapy alone in about 360 patients ages 35 to 70 years...